2022-04-13 | NYSE: IBM | Press release

NEW YORK, April 13, 2022 /PRNewswire/ — Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against:

The company, its officers or directors have misrepresented and/or failed to disclose that: (1) the safety concerns regarding Xeljanz extend to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and delay approval of additional treatment indications for Rinvoq; and (3) therefore, the defendants’ statements about the company’s business, operations and prospects lacked a reasonable basis. As a result of the alleged wrongful acts and omissions, AbbVie’s securities experienced a significant decline in market value and AbbVie’s investors suffered significant damages.

International Business Machines Corporation (NYSE:IBM)

Please contact only if you have acquired shares before April 4, 2017.

After market close on October 16, 2018, IBM disclosed a shortfall and disappointing growth in 3Q2018 associated with the company’s Strategic Imperatives and CAMSS business lines, in particular its Cloud business line.

On October 20, 2021, after market close, the Company issued a press release announcing its 3Q2021 results. The Company announced its total sales for the quarter of $17.62 billiona lack of $191.84 million based on analysts’ estimates. The main culprit is the Cloud & Cognitive Software segment, which achieved a turnover of $5.69 billiona shortfall of approximately $80 million based on analyst estimates of $5.77 billion. More than 42% of $191 million the shortfall was attributable to the company’s Cloud & Cognitive Software segment – where most of the strategic revenue generated by the fraudulent scheme and unwarranted reclassification of revenue from non-strategic to strategic has historically gone.

ABBV or IBM shareholders should contact Fletcher Moore, Esq. by email to fmoore@moorekuehn.com or call (212) 709-8245.

Moore Kuehn is a New York-based law firm with attorneys representing investors, shareholders, unitholders and consumers. Lawyer advertisement. Prior results do not guarantee similar results.

Moore Kuehn, LLC

Fletcher Moore, Esq.

30 Wall Street, 8and Stage

New YorkNew York 10005

fmoore@moorekuehn.com

(212) 709-8245

See original content to download multimedia: https://www.prnewswire.com/news-releases/moore-kuehn-pllc-encourages-investors-of-abbvie-inc-or-international-business-machines-corporation-to -contact-lawyer-firm-301525417.html